Surgery Partners Stock

Surgery Partners EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Surgery Partners (SGRY) as of Jul 31, 2026 is 5.13. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 5.73 — a change of -10.45% (lower).

EV/EBIT

5.13

YoY

-10.45%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Surgery Partners is 2026 5.13 . EV/EBIT (Enterprise Value to EBIT) of Surgery Partners was 2025 5.73 . It decreases by -10.45% lower compared to the previous year.

The Surgery Partners EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
3.24 base
Jan 1, 2020
7.75 base
Jan 1, 2021
14.94 base
Jan 1, 2022
8.22 base
Jan 1, 2023
12.27 base
Jan 1, 2024
7.66 base
Jan 1, 2025
5.05 base
Jan 1, 2026 (e)
4.78 base
YEARPRICE-TO-EBIT
2026 est 4.78
2025 5.05
2024 7.66
2023 12.27
2022 8.22
2021 14.94
2020 7.75
2019 3.24
2018 6.04
2017 2.92
2016 2.36
2015 4.33
2014 -
2013 -
2012 -
2011 -
Access this data via the Eulerpool API

Surgery Partners Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Surgery Partners's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Surgery Partners's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Surgery Partners's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Surgery Partners grows earnings faster than its peers.

Surgery Partners Stock analysis

What does Surgery Partners do? Surgery Partners Inc is an American company specializing in specialized surgical services in the United States. It was founded in 1997 and is headquartered in Nashville, Tennessee. The company focuses on outpatient surgical procedures, providing a variety of medical services including eye surgery, endoscopy, ENT surgery, gynecology, orthopedic surgery, plastic surgery, and urology. Surgery Partners has over 180 surgical centers and practices in 32 states. It expanded its services through the acquisition of Symbion Healthcare in 2017, offering anesthesia services, pain management, diagnostics, and laboratory services. The company also emphasizes excellent service and has partnerships with hospitals to expand its surgical services. Surgery Partners is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Surgery Partners stock

EV/EBIT (Enterprise Value to EBIT) of Surgery Partners is 5.13 in 2026.

Access this data via the Eulerpool API

Valuation — Surgery Partners

All Key Metrics — Surgery Partners